ILMN — Illumina Inc

Illumina Inc (ILMN) is a diagnostics & research company listed on NASDAQ. It is led by Jacob Thaysen Ph.D., based in 5200 Illumina Way, San Diego, CA, United States, 92122, with about 8,970 employees. Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Latest reported ILMN revenue for 2025-12-28 was $4.34B. Net income was $850.0M. Revenue was up 300.6% from 2025-09-28 to 2025-12-28. ILMN currently screens at market cap $15.84B.

Use this ILMN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ILMN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ILMN SEC filings page. Lician reads the product cache first so this HTML stays unique to Illumina Inc even when a live quote feed is slow.